NasdaqCM - Nasdaq Real Time Price USD

SciSparc Ltd. (SPRC)

4.2700 +0.0865 (+2.07%)
At close: May 22 at 4:00:00 PM EDT
4.0000 -0.2700 (-6.32%)
After hours: May 22 at 5:54:13 PM EDT
Chart Range Bar
Loading chart for SPRC
Chart does not reflect overnight price.
  • Previous Close 4.1835
  • Open 4.2500
  • Bid 3.0600 x 200
  • Ask 5.2400 x 200
  • Day's Range 4.1000 - 4.4400
  • 52 Week Range 2.9800 - 80.1000
  • Volume 19,525
  • Avg. Volume 419,617
  • Market Cap (intraday) 2.448M
  • Beta (5Y Monthly) 1.33
  • PE Ratio (TTM) 0.04
  • EPS (TTM) 98.0700
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufacture SCI-110, palmitoylethanolamide oral tablets and CannAmide in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

scisparc.com

2

Full Time Employees

December 31

Fiscal Year Ends

Recent News: SPRC

View More

Performance Overview: SPRC

Trailing total returns as of 5/22/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

SPRC
65.11%
S&P 500 (^GSPC)
9.17%

1-Year Return

SPRC
92.71%
S&P 500 (^GSPC)
27.93%

3-Year Return

SPRC
99.87%
S&P 500 (^GSPC)
78.25%

5-Year Return

SPRC
99.98%
S&P 500 (^GSPC)
79.83%

Earnings Trends: SPRC

View More

Earnings Per Share

 

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY21
Revenue --
Earnings --

Q3

FY17

Q4

FY17

Q1

FY21

Q2

FY21

-3M
-2M
-2M
-1M
-500K
0
 

Statistics: SPRC

View More

Valuation Measures

Annual
As of 5/22/2026
  • Market Cap

    2.45M

  • Enterprise Value

    -1.78M

  • Trailing P/E

    0.04

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.62

  • Price/Book (mrq)

    0.58

  • Enterprise Value/Revenue

    5.44

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    -1,281.49%

  • Revenue (ttm)

    1.31M

  • Net Income Avi to Common (ttm)

    -6.48M

  • Diluted EPS (ttm)

    98.0700

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    --

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    --

Compare To: SPRC

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights: SPRC

Research Reports: SPRC

View More

People Also Watch